Comparative Pharmacology
Head-to-head clinical analysis: ADAPALENE versus ATRALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADAPALENE versus ATRALIN.
ADAPALENE vs ATRALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoic acid receptor agonist; binds to RARβ/γ nuclear receptors, modulating gene expression to normalize follicular keratinization and reduce comedogenesis.
Retinoic acid receptor (RAR) agonist; binds to RARs (alpha, beta, gamma) to modulate gene transcription, regulating cell growth, differentiation, and apoptosis.
Apply a pea-sized amount topically to affected areas once daily in the evening.
20-30 mg/m² orally once daily for 5 consecutive days, repeated every 4 weeks.
None Documented
None Documented
The terminal elimination half-life of adapalene after topical application is approximately 17 hours (range 7–51 hours), reflecting slow release from skin depot and hepatic clearance. This supports once-daily dosing.
Clinical Note
moderateAdapalene + Gatifloxacin
"Adapalene may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateAdapalene + Rosoxacin
"Adapalene may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateAdapalene + Levofloxacin
"Adapalene may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateAdapalene + Trovafloxacin
"Adapalene may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is approximately 1-2 hours in adults, but may be prolonged in patients with hepatic impairment or severe renal disease. Due to its short half-life and extensive protein binding, drug concentrations may not correlate directly with clinical response.
Adapalene is eliminated primarily via biliary excretion into feces. After oral administration in animals, approximately 80% of the dose is recovered in feces and about 10% in urine; for topical application, systemic absorption is minimal and the small absorbed fraction undergoes similar hepatobiliary elimination.
Primarily hepatic metabolism via CYP450 isoenzymes, with metabolites excreted in bile and urine. Approximately 60-70% of the dose is eliminated in feces (as unchanged drug and metabolites) and 15-25% in urine (mainly as metabolites). Less than 1% is excreted unchanged in urine.
Category D/X
Category C
Retinoid
Retinoid